- Home
- MYSZ vs CANF Comparison
MYSZ vs CANF Comparison
Compare MYSZ & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYSZ
- CANF
- Stock Information
- Founded
- MYSZ 1999
- CANF 1994
- Country
- MYSZ Israel
- CANF Israel
- Employees
- MYSZ N/A
- CANF N/A
- Industry
- MYSZ Computer Software: Prepackaged Software
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MYSZ Technology
- CANF Health Care
- Exchange
- MYSZ Nasdaq
- CANF Nasdaq
- Market Cap
- MYSZ 8.2M
- CANF 9.4M
- IPO Year
- MYSZ N/A
- CANF N/A
- Fundamental
- Price
- MYSZ $2.07
- CANF $1.54
- Analyst Decision
- MYSZ Strong Buy
- CANF Strong Buy
- Analyst Count
- MYSZ 1
- CANF 2
- Target Price
- MYSZ $3.00
- CANF $14.00
- AVG Volume (30 Days)
- MYSZ 8.2M
- CANF 117.2K
- Earning Date
- MYSZ 11-14-2024
- CANF 02-03-2025
- Dividend Yield
- MYSZ N/A
- CANF N/A
- EPS Growth
- MYSZ N/A
- CANF N/A
- EPS
- MYSZ N/A
- CANF N/A
- Revenue
- MYSZ $9,632,000.00
- CANF $667,000.00
- Revenue This Year
- MYSZ $35.62
- CANF $409.56
- Revenue Next Year
- MYSZ $12.88
- CANF N/A
- P/E Ratio
- MYSZ N/A
- CANF N/A
- Revenue Growth
- MYSZ 43.89
- CANF N/A
- 52 Week Low
- MYSZ $1.05
- CANF $1.29
- 52 Week High
- MYSZ $9.40
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- MYSZ 42.86
- CANF 42.93
- Support Level
- MYSZ $2.24
- CANF $1.55
- Resistance Level
- MYSZ $3.15
- CANF $1.64
- Average True Range (ATR)
- MYSZ 0.55
- CANF 0.10
- MACD
- MYSZ -0.21
- CANF 0.01
- Stochastic Oscillator
- MYSZ 1.35
- CANF 11.76
About MYSZ My Size Inc.
My Size Inc is a USA based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers, and licensing cloud-enabled software subscriptions, associated software maintenance and support.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).